Newsletter | January 29, 2025

01.29.25 -- Tune Therapeutics' 2025 Epigenome Editing Outlook

SPONSOR

Registration for INTERPHEX 2025 is officially live! Happening April 1-3 in NYC, INTERPHEX is the largest pharmaceutical and biotechnology event of the year. Join over 9,000 industry professionals and 500+ exhibitors from all over the world as we take you through the entire pharmaceutical product development lifecycle. Follow the link to claim your FREE Exhibit Hall badge.

FEATURED EDITORIAL

The Marriage Of Science & Strategy: Identifying mRNA Therapeutics' Value Propositions

Though it’s not a question we can answer fully yet, in the first of this two-part article, CureVac CEO Alexander Zehnder starts us down the path of answering a critical question about our RNA therapies: In what ways can and should our mRNA products add value to our patients’ lives?

Tune Therapeutics' 2025 Epigenome Editing Outlook

Chief Scientific Officer Derek Jantz talks about recent key innovations in gene therapy and RNA technology while considering what milestones we might see in 2025.

FDA Issues New Guidance: Nonclinical Safety Assessment Of Oligonucleotide-Based Therapeutics

FDA's CDER recently issued a draft guidance: Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics. This article provides a summary and analysis.

What Innovations Could Help Us Overcome Preclinical Model Limitations For RNA-LNPs?

In this Advancing RNA Live clip, BioNTech’s Ben Muir and Hopewell Therapeutics’ Kate Zhang share their perspectives on the most exciting novel screening methods, innovative preclinical models, and next-gen technologies they hope can/will eventually help us bridge the translation gap between preclinical models and the clinic.

INDUSTRY INSIGHTS

Assigning IR Absorption Bands For RNA Building Blocks Using MMS

This study analyzes the vibrational modes of RNA base signatures using Microfluidic Modulation Spectroscopy (MMS), revealing insights into electronic environments and molecular interactions.

mRNA Product Purification Process Strategies

Impurities from IVT can induce undesired immune responses and negatively impact translation efficiency. Explore the pros and cons of each option for mRNA purification.

Study Viral Infection In Resting Human CD4+ T Cells

Explore a study proving how synthetic single guide RNAs were used to optimize the editing conditions for resting human CD4+ T cells and maintain high cell viability for several weeks post Nucleofection.

Large Scale Purification Of Oligonucleotides With IEX

As oligonucleotide-based drugs gain momentum in therapeutic development, refining their manufacturing processes through solutions like ion exchange chromatography (IEX) becomes crucial.

Key Benefits Of PCR-Based mRNA Manufacturing For Clinical Development

To unlock the potential of your mRNA therapies and accelerate your development and manufacturing program, discover the benefits of a novel PCR-based mRNA drug substance manufacturing process.

Lowering The Lipid Barrier To RNA-LNP Therapeutics

Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.

Essential Strategies For IVT Optimization

Optimizing in vitro transcription (IVT) for mRNA is crucial to improving the stability of these molecules and enabling their large-scale production.

Evolving Into Biopharma 4.0: A Stepwise Journey Of Digital Transformation

Watch to discover how incremental steps can transform your processes using digitalization and automation.